Opinion|Videos|June 27, 2024
Sequencing CDK4/6 Inhibitors in HR+/HER2- Breast Cancer Treatment
An oncologist specializing in breast cancer treatment reviews the latest guideline recommendations for systemic therapies in HR+/HER2- breast cancer, comparing the available CDK4/6 inhibitors and discussing considerations for optimal treatment sequencing.
Advertisement
Episodes in this series
- What are the current guideline-recommended systematic treatments for HR-positive/HER2-negative (HR+/HER2-) breast cancer?
- What are some of the differences between the CDK 4/6 inhibitors used in the management of HR+/HER2-? What factors drive treatment decision-making between available options?
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
Semaglutide More Than Doubled Likelihood of MASH Resolution
2
Once-Daily Pill Zasocitinib Clears Psoriasis at Toughest Sites
3
Wildfire Smoke Raises Asthma Risks as Fires Worsen Air Quality Across North America
4
Why Cutting Trial Red Tape Won't Fix Clinical Trial Design
5